Cariprazine is indicated for the treatment of schizophrenia and Acute treatment of manic or mixed episodes associated with bipolar I disorder. Cariprazine was developed by Richter Gedeon Vegyeszeti Gyar Rt..
The API has now reached off-patent status, after being launched in 2015.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Cariprazine was exported from India in 2023 , with an average price over the period of $20157 /kg.
The key suppliers were Lee Pharma, with a focus on markets in Central & South America.

For enquiries regarding more detailed trade data of Cariprazine and many others, contact info@pharmacheminvestor.com